Rapid response through the entrepreneurial capabilities of academic scientists
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Entrepreneurship Studies and Influences · Biomedical and Engineering Education
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Friedrichs, S. & Bowman, D. M. Nat. Nanotechnol. 16, 362–364 (2021).10.1038/s41565-021-00901-8 ↗
2. Maine, E. & Thomas, V. J. Nat. Nanotechnol. 12, 93–98 (2017).10.1038/nnano.2017.1 ↗
3. Zucker, L. G. & Darby, M. R. Entrepreneurs, Star Scientists, and Biotechnology (NBER, 1998); https://www.nber.org/reporter/fall-1998/entrepreneurs-star-scientists-and-biotechnology
4. Thomas, V. J., Bliemel, M., Shippam, C. & Maine, E. Technovation 96, 102153 (2020).10.1016/j.technovation.2020.102153 ↗
5. Bolzani, D., Munari, F., Rasmussen, E. & Toschi, L. The Journ. of Tech. Trans. 46, 335–365 (2021).10.1007/s10961-020-09788-4 ↗
6. Leih, S. & Teece, D. Acad. Manag. Perspect 30, 182–210 (2016).10.5465/amp.2015.0022 ↗
7. Roberts, E. B., Murray, F. & Kim, J. D. Martin Trust Center for MIT Entrepreneurship 15, 1–55 (2015).
8. Perkmann, M. et al. Res. Policy 42, 423–442 (2013).10.1016/j.respol.2012.09.007 ↗
9. Pisano, G. P. Ind. and Corp. Change 19, 465–482 (2010).10.1093/icc/dtq013 ↗
10. Arora, A., Belenzon, S., Patacconi, A. & Suh, J. Innov. Policy Econ. 20, 39–93 (2020).10.1086/705638 ↗
11. Arora, A., Belenzon, S., Patacconi, A. & Suh, J. Harv. Bus. Rev. https://hbr.org/2019/11/why-the-u-s-innovation-ecosystem-is-slowing-down (2019).
12. New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials (AbCellera, 2021); https://www.abcellera.com/news/new-abcellera-discovered-antibody-that-neutralizes-viral-variants-of-covid-19-ly-cov1404-enters-clinical-trials
13. Teece, D. J. Strat. Manage. Journ. 28, 1319–1350 (2007).10.1002/smj.640 ↗
14. Helfat, C. E. & Peteraf, M. Strat. Manage. Journ. 36, 831–850 (2015).10.1002/smj.2247 ↗
15. Gurdon, M. A. & Samsom, K. J. Technovation 30, 207–214 (2010).10.1016/j.technovation.2009.10.004 ↗
16. Rasmussen, E. Int. Small Bus. Journ. 29, 448–471 (2011).10.1177/0266242610385395 ↗
17. Freeman, C. The Economics of Industrial Innovation 2nd edn (MIT Press,1982).
18. Maine, E. & Garnsey, E. Res. Policy 35, 375–393 (2006).10.1016/j.respol.2005.12.006 ↗
19. Maine, E. & Seegopaul, P. Nat. Mater. 15, 487–491 (2016).10.1038/nmat4625 ↗
20. Beckman, C. M. & Burton, M. D. Org. Sci. 19, 3–24 (2008).10.1287/orsc.1070.0311 ↗
21. AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 (Eli Lilly, 2020); https://investor.lilly.com/news-releases/news-release-details/ab
22. License agreement between The University of British Columbia and Abcellera Biologics Inc. (The University of British Columbia, 2013); https://www.sec.gov/Archives/edgar/data/0001703057/000119312520299507/d29983dex106.htm
23. Hsu, D. H. & Ziedonis, R. H. Patents as quality signals for entrepreneurial ventures. In Proc. Acad. of Manage 1–6 (Academy of Management, 2008).10.5465/ambpp.2008.33653924 ↗
24. Singhal, A. et al. Methods for assaying cellular binding interactions. US patent 36523710P (2019).
25. Hansen, C., Lecault, V., Piret, M., Singhal, A. System and method for microfluidic cell culture. US patent 36221310P (2020).
26. Lecault, V. et al. Nat. Methods 8, 581–586 (2011).10.1038/nmeth.1614 ↗
27. Hansen, C. L., Sommer, M. O. & Quake, S. R. Systematic investigation of protein phase behavior with a microfluidic formulator. Proc. Natl. Acad. Sci. 101, 14431–14436 (2004).10.1073/pnas.0405847101 ↗
28. Silcoff, S. With Historic Financing, AbCellera Becomes Champion of Canada’s Surging Biotechnology Sector (Globe & Mail, 2020); https://www.theglobeandmail.com/business/article-bc-drug-maker-abcellera-raises-expected-ipo-price-amid-huge-investor/
29. Murray, F. The role of academic inventors in entrepreneurial firms: sharing the laboratory life. Res. Policy 33, 643–659 (2004).10.1016/j.respol.2004.01.013 ↗
30. Form S-1 Registration Statement: AbCellera Biologics Inc. (SEC, 2020); https://www.sec.gov/Archives/edgar/data/1703057/000119312520299507/d29983ds1.htm
31. AbCellera Closes Seed Round of Financing (AbCellera, 2014); https://investors.abcellera.com/news/news-releases/2014/AbCellera-Closes-Seed-Round-of-Financing/default.aspx
32. Niosi, J. & McKelvey, M. Journ. of Evol. Econ. 28, 1081 (2018).10.1007/s00191-018-0561-9 ↗
33. Linton, J. D. & Xu, W. Trends in Biotech. 39, 107–110 (2021).10.1016/j.tibtech.2020.06.013 ↗
34. Identifying a Potential Drug Candidate for Human Testing in 90 Days (AbCellera, 2020); https://www.abcellera.com/post/identifying-a-potential-drug-candidate-for-human-testing
35. McKelvey, M. Health Biotechnology: Emerging Business Models and Institutional Drivers (OECD, 2008); https://www.oecd.org/sti/futures/long-termtechnologicalsocietalchallenges/40923107.pdf
36. Christensen, C. M., Musso, C. S. & Anthony, S. D. Res.-Tech. Manage 4, 12–18 (2004).
37. How Much Has Been Obligated for COVID-19 Vaccines Under the DOD and HHS Partnership? (GAO Science, 2021); https://ows.gaoinnovations.gov/the-funding
38. Sonne, P. How a Secretive Pentagon Agency Seeded the Ground for a Rapid Coronavirus Cure (The Washington Post, 2020); https://www.washingtonpost.com/national-security/how-a-secretive-pentagon-agency-seeded-the-ground-for-a-rapid-coronavirus-cure/2020/07/30/ad1853c4-c778-11ea-a9d3-74640f25b953_story.html
39. Galindez, G. et al. Nat. Comp. Sci. 1, 33–41 (2021).10.1038/s43588-020-00007-6 ↗
40. Beigel, J. H., Tomashek, K. M. & Dodd, L. E. et al. New Eng. Journ. of Med. 19, 1813–1826 (2020).10.1056/NEJMoa2007764 ↗
41. Maine, E., Thomas, V. J. & Utterback, J. J. Eng. Technol. Manage. 32, 1–25 (2014).10.1016/j.jengtecman.2013.10.007 ↗
42. Eesley, C. E., Hsu, D. H. & Roberts, E. B. Strateg. Manag. J. 35, 1798–1817 (2014).10.1002/smj.2183 ↗
43. Thomas, V. J. & Maine, E. Int. J. Entrepreneurship Small Bus. 37, 271–287 (2019).10.1504/IJESB.2019.100108 ↗
44. Maine, E. M., Shapiro, D. M. & Vining, A. R. Small Bus. Econ. 34, 127–146 (2010).10.1007/s11187-008-9104-3 ↗
45. Rasmussen, E., Benneworth, P. & Gulbrandsen, M. in Research Handbook on Start-Up Incubation Ecosystems (Edward Elgar Publishing. (2020).
46. Expanding integrative basic and applied research to accelerate service to society. HRA https://hibar-research.org (accessed March 2022).
47. Backgrounder – Government of Canada Investments in COVID-19 Vaccines, Therapeutics and Biomanufacturing Capacity (Government of Canada, 2021); https://www.canada.ca/en/innovation-science-economic-development/news/2021/02/backgrounder--government-of-canada-investments-in-covid-19-vaccines-and-biomanufacturing-capacity.html
48. Financing the Global Commons for Pandemic Preparedness and Response (Financing the Global Commons for Pandemic Preparedness and Response, 2021); https://pandemic-financing.org
49. Kisby, T., Yilmazer, A. & Kostarelos, K. Nat. Nanotechnol. 16, 843–852 (2021).10.1038/s41565-021-00946-9 ↗
50. Bigini, P. et al. Nat. Nanotechnol. 16, 1164–1175 (2021).10.1038/s41565-021-01001-3 ↗
51. Lazonick, W. & Mazzucato, M. Ind. And Corp. Change 22, 1093–1128 (2013).10.1093/icc/dtt019 ↗